PharmaBlock Sciences (Nanjing) Third Quarter 2024 Earnings: EPS: CN¥0.16 (vs CN¥0.20 in 3Q 2023)
PharmaBlock Sciences (Nanjing) (SZSE:300725) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥383.0m (down 14% from 3Q 2023).
- Net income: CN¥33.1m (down 18% from 3Q 2023).
- Profit margin: 8.6% (down from 9.0% in 3Q 2023).
- EPS: CN¥0.16 (down from CN¥0.20 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PharmaBlock Sciences (Nanjing) Earnings Insights
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 5.6% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for PharmaBlock Sciences (Nanjing) you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300725
PharmaBlock Sciences (Nanjing)
Provides chemistry products and services throughout the pharmaceutical research and development, and commercial production.
Reasonable growth potential with adequate balance sheet.
